1234489-08-7

Upstream product

• 31651-76-0 1-naphthyl dichlorophosphate 
• 90-15-3 α-naphthol 
• 41324-79-2 (S)-methyl-2-amino cyclohexyl acetate hydrochloride 

Downstream Products

• 1234490-89-1 (2S)-cyclohexyl 2-((((2R,3R,4R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalene-1-yloxy)phosphorylamino)propanoate 
• 1431557-47-9 6-O-methyl-2’-fluoro-2’-deoxyguanosine-5’-O-naphtyl(cyclohexoxy-L-alaninyl)phosphate 
• 1431557-61-7 2-amino-2’-fluoro-2’-deoxyadenosine-5’-O-naphthyl(cyclohexoxy-L-alaninyl)phosphate 
• 1443987-76-5 C₄₀H₄₂F₂NO₁₂P 
• 1430067-82-5 2-deoxy-2,2-difluoro-β-D-arabinofuranose (P_R)-1-O-naphth-1-yl-(cyclohexyloxy-alaninyl)phosphate 
• 1430067-83-6 2-deoxy-2,2-difluoro-β-D-arabinofuranose (P_S)-1-O-naphth-1-yl-(cyclohexyloxy-alaninyl)phosphate 
• 1430067-98-3 2-deoxy-2-fluoro-α-D-arabinofuranose (P_R)-1-O-naphth-1-yl-(cyclohexoxy-alaninyl)phosphate 
• 1430067-99-4 2-deoxy-2-fluoro-α-D-arabinofuranose (P_S)-1-O-naphth-1-yl-(cyclohexoxy-alaninyl)phosphate 
• 1443987-42-5 C₄₀H₄₃FNO₁₂P 
• 1234488-79-9 C₃₃H₄₁N₆O₉P 

Relevant academic research and scientific papers

Application of ProTide technology to gemcitabine: A successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development

Gemcitabine is a nucleoside analogue commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance. The addition of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms. We have synthesized a series of gemcitabine phosphoramidate prodrugs and screened for cytostatic activity in a range of different tumor cell lines. Among the synthesized compounds, one in particular (NUC-1031, 6f) was shown to be potent in vitro. Importantly, compared with gemcitabine, 6f activation was significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it was resistant to cytidine deaminase-mediated degradation. Moreover, 6f showed a significant reduction in tumor volumes in vivo in pancreatic cancer xenografts. The ProTide 6f is now in clinical development with encouraging efficacy signals in a Phase I/II study, which strongly supports the ProTide approach to generate promising new anticancer agents.

Synthesis and Biological Evaluation of Purine 2′-Fluoro-2′-deoxyriboside ProTides as Anti-influenza Virus Agents

2′-Fluoro-2′-deoxyguanosine has been reported to have potent anti-influenza virus activity invitro and invivo. Herein we describe the synthesis and biological evaluation of 6-modified 2′-fluoro-2′-deoxyguanosine analogues and their corresponding phosphora

PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS

Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.